Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of BI 754091 monotherapy and BI 754091 + BI 754111 in Asian patients with advanced solid tumours
jRCT2080223817Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of ezabenlimab and miptenalimab in Nonhematologic neoplasms (2 arms), sponsored by Boehringer Ingelheim. Started Feb 2018; status: completed.
02
Drugs
ezabenlimabmiptenalimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080223817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223817.